← Back to Screener
Beyond Air, Inc. Common Stock (XAIR)
Price$0.45
Favorite Metrics
Price vs S&P 500 (26W)-84.97%
Price vs S&P 500 (4W)-43.37%
Market Capitalization$6.00M
All Metrics
Book Value / Share (Quarterly)$0.97
P/TBV (Annual)1.82x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)62.09%
Cash Flow / Share (Quarterly)$-2.63
Price vs S&P 500 (YTD)-33.22%
Gross Margin (TTM)1.82%
Net Profit Margin (TTM)-447.73%
EPS (TTM)$-5.43
10-Day Avg Trading Volume0.48M
EPS Excl Extra (TTM)$-5.43
Revenue Growth (5Y)-13.66%
EPS (Annual)$-13.77
ROI (Annual)-199.35%
Gross Margin (Annual)-44.89%
Net Profit Margin (5Y Avg)-2120.89%
Cash / Share (Quarterly)$1.39
Revenue Growth QoQ (YoY)104.66%
ROA (Last FY)-155.10%
Revenue Growth TTM (YoY)129.04%
EBITD / Share (TTM)$-4.38
ROE (5Y Avg)-173.09%
Operating Margin (TTM)-418.27%
Cash Flow / Share (Annual)$-10.68
P/B Ratio0.74x
P/B Ratio (Quarterly)0.69x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)3.08x
Net Interest Coverage (TTM)-47.33x
ROA (TTM)-98.48%
EPS Incl Extra (Annual)$-13.77
Current Ratio (Annual)3.20x
Quick Ratio (Quarterly)3.83x
3-Month Avg Trading Volume5.19M
52-Week Price Return-89.23%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.84
P/S Ratio (Annual)1.62x
Asset Turnover (Annual)0.12x
52-Week High$5.84
Operating Margin (5Y Avg)-2130.70%
EPS Excl Extra (Annual)$-13.77
CapEx CAGR (5Y)171.34%
Tangible BV CAGR (5Y)-6.91%
26-Week Price Return-80.98%
Quick Ratio (Annual)1.60x
13-Week Price Return-42.47%
Total Debt / Equity (Annual)0.72x
Current Ratio (Quarterly)5.12x
Enterprise Value$21.333
Revenue / Share Growth (5Y)3.80%
Asset Turnover (TTM)0.22x
Book Value / Share Growth (5Y)23.91%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)2.36x
Pretax Margin (Annual)-1308.48%
Cash / Share (Annual)$1.68
3-Month Return Std Dev312.42%
Net Income / Employee (TTM)$-1
ROE (Last FY)-343.26%
Net Interest Coverage (Annual)-13.69x
EPS Basic Excl Extra (Annual)$-13.77
Receivables Turnover (TTM)7.74x
Total Debt / Equity (Quarterly)2.71x
EPS Incl Extra (TTM)$-5.43
ROI (TTM)-129.07%
P/S Ratio (TTM)0.87x
Pretax Margin (5Y Avg)-2203.14%
Revenue / Share (Annual)$1.09
Tangible BV / Share (Annual)$2.99
Price vs S&P 500 (52W)-119.06%
Year-to-Date Return-30.58%
5-Day Price Return-37.59%
EPS Normalized (Annual)$-13.77
ROA (5Y Avg)-88.40%
Net Profit Margin (Annual)-1258.43%
Month-to-Date Return-26.98%
Cash Flow / Share (TTM)$-2.15
EBITD / Share (Annual)$-13.14
Operating Margin (Annual)-1268.12%
LT Debt / Equity (Annual)0.68x
ROI (5Y Avg)-122.91%
LT Debt / Equity (Quarterly)2.71x
EPS Basic Excl Extra (TTM)$-5.43
P/TBV (Quarterly)0.79x
P/B Ratio (Annual)1.66x
Inventory Turnover (TTM)3.28x
Pretax Margin (TTM)-462.58%
Book Value / Share (Annual)$3.29
Price vs S&P 500 (13W)-43.15%
Beta0.35x
P/FCF (Annual)4.69x
Revenue / Share (TTM)$0.80
ROE (TTM)-279.58%
52-Week Low$0.43
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.00
4.00
4.00
4.00
Industry Peers — Surgical & Medical Instruments(108)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
XAIRBeyond Air, Inc. Common Stock | 0.87x | -13.66% | 1.82% | -418.27% | $0.45 |
SYKStryker Corporation | 5.15x | 11.84% | 64.57% | 19.43% | $338.38 |
BSXBoston Scientific Corp. | 4.76x | 15.16% | 69.01% | 18.00% | $63.42 |
MMM3M Company | 3.18x | -4.97% | 39.92% | 18.55% | $150.55 |
MDLNMedline Inc. Class A common stock | 2.21x | — | 26.44% | 7.78% | $46.94 |
BDXBecton, Dickinson and Co. | 2.01x | 6.32% | 46.42% | 12.15% | $154.82 |
RMDResMed Inc. | 6.06x | 11.72% | 60.85% | 33.70% | $224.72 |
DXCMDexCom, Inc. | 5.23x | 19.33% | 62.09% | 19.56% | $61.23 |
WSTWest Pharmaceutical Services, Inc. | 6.22x | 7.44% | 35.91% | 19.03% | $269.81 |
PODDInsulet Corporation | 5.31x | 24.53% | 71.63% | 12.92% | $201.47 |
PENPenumbra, Inc. | 9.31x | 20.16% | 67.14% | 13.48% | $331.47 |
About
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a proprietary nitric oxide (NO) generator and delivery system, extracting NO from ambient air for inhaled therapeutic treatment. The company is advancing its technology for pulmonary hypertension and lower respiratory tract infections.